AllSci News
J&J/Nanbiotix’s nanoparticle radioenhancer shows local control signal in recurrent NSCLC
A Phase I trial of Johnson & Johnson-licensed JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer developed by Nanobiotix S.A. (Euronext: NANO;...
AstraZeneca's Etcamah misses Phase III first-line breast cancer endpoint
AstraZeneca announced that the SERENA-4 Phase III trial of camizestrant (Etcamah) in combination with Pfizer's Ibrance (palbociclib) has failed to meet its...
Ivonescimab cuts death risk 27% versus Keytruda in Phase III NSCLC trial
Updated overall survival data from the Phase III HARMONi-2 trial show that ivonescimab monotherapy reduced the risk of death by 27% compared with Merck's...
Roche-partnered Tam-Peli cuts death risk 54% in Phase III SCLC trial
China-based MediLink Therapeutics presented Phase III data showing its B7-H3-targeted antibody-drug conjugate (ADC) tambotatug pelitecan (Tam-Peli)...
Endo Axiom takes oral nanoparticle insulin into first-in-human trial
Australia-based Endo Axiom Pty Ltd has dosed its first human participants with an oral nanoparticle-encapsulated insulin formulation, marking the company's...
Teva raises USD 4.9bn to refinance higher-coupon debt
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) priced a multi-tranche senior notes offering totaling approximately USD 4.9 billion equivalent, with...
IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer
New Jersey-based IMUNON, Inc. (Nasdaq: IMNN) entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part...
Exegenesis and Modalis combine muscle-targeting AAV with epigenome editing for preclinical DMD candidate
Exegenesis Bio and Japan-based Modalis Therapeutics Corporation (Tokyo: 4883) signed a research collaboration and license agreement to advance MDL-201, a...
Yarrow raises USD 150m to advance first-in-class Graves' disease antibody into Phase II
Connecticut-based Yarrow Bioscience, Inc. (Nasdaq: YARW) announced the pricing of an underwritten public offering of 5,769,231 shares of common stock at USD...
NeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor
London-based neurotechnology company NeuroHarmonics is set to begin recruiting patients for the first clinical evaluation of its non-invasive deep-brain...
Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I
China-based Gan & Lee Pharmaceuticals Co., Ltd. has dosed the first participant in a Phase I study of GZC8072, an oral peptide glucagon-like peptide-1...
Johns Hopkins tests pancreatic TLR4–hyperglycemia axis as driver of necrotizing enterocolitis
Johns Hopkins University has received a USD 2.5 million NIH R01 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to...
FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027
The US FDA has extended its review of the New Drug Application (NDA) for zanzalintinib, an oral kinase inhibitor, in combination with atezolizumab...
OMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia
UK-based OMass Therapeutics has registered a Phase I trial of OMS1620, an oral small-molecule melanocortin-2 receptor (MC2R) antagonist being developed for...
Navion Neurosciences secures USD 10.8m to pursue sodium-channel drugs for epilepsy and pain
Charlottesville, Virginia-based Navion Neurosciences, Inc. announced first closing of a USD 10.8 million seed financing round to advance precision...
The AllSci Brief
Free, systematic R&D and deal news. Daily.